



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

*zle*

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/602,035	06/23/2003	Mizuo Miyazaki	CPR-00101.P.1-US	9541

33432 7590 04/18/2007  
KILYK & BOWERSOX, P.L.L.C.  
400 HOLIDAY COURT  
SUITE 102  
WARRENTON, VA 20186

EXAMINER
----------

AUDET, MAURY A

ART UNIT	PAPER NUMBER
----------	--------------

1654

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	04/18/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/602,035	<b>Applicant(s)</b> MIYAZAKI, MIZUO	
	<b>Examiner</b> Maury Audet	<b>Art Unit</b> 1654	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 23 January 2007.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-36 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-36 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 23 June 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

Art Unit: 1654

### DETAILED ACTION

Applicant's amendment and response of 1/23/07 is acknowledged. Claims 1-34 and new claims 35-36 are pending and examined on the merits.

#### *Election/Restrictions*

As previously noted, Applicant's election without traverse of Group I, claims 1-32, as drawn to method of using the elected invention compound Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub> in the reply filed on 05/26/2006 is acknowledged. The Examiner is willing to rejoin Group II, the composition as drawn to the elected invention compound Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub>, as to both Group I and Group II. Claims 1-34 are examined on the merits. Claims 1-34 have been examined only in so far as they read on the above elected invention and rejoined composition/compound thereto. *However, Applicant is requested amend the claims in scope to the above elected/rejoined group consisting of the active agent Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub>.*

#### *Claim Rejections - 35 USC § 102*

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The rejection of claims 33-34 are rejected under 35 U.S.C. 102(b) as being anticipated by Powers et al. (US 5,543,396; also cited in IDS of 04/23/04, P5) is maintained for the reasons of record. Applicant's arguments have been considered but are not found persuasive. The claims

Art Unit: 1654

are to products. Any amount of the elected product, as taught by Powers, teaches the product and an effective amount to reduce adhesion formation to some degree.

The remainder of the rejection is repeated below for continuity of record:

Powers et al. teach a pharmaceutical composition in any form (inherently containing a diluent or excipient since can be in the form of e.g. tablet, aqueous or oily suspension, etc.) (col. 16, lines 23-40), comprising the elected compound of the invention Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub> (e.g. Example 17), described as the “best inhibitor for [serine proteases] chymotrypsin and chymotrysin-like enzymes” (col. 5, lines 40-44; col. 3, lines 50-53), which are involved in “tissue remodeling” [e.g. tissue adhesion formation] (col. 1, lines 41-43).

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The rejection of claims 1-34 and new claims 35-36 under 35 U.S.C. 103(a) as being unpatentable over Powers et al. (US 5,543,396; also cited in IDS of 04/23/04, P5) in view of Scharpe et al. (US 2002/0061839 A1), is maintained for the reasons of record. Applicant's arguments have been considered but are not found persuasive. Namely, as Applicant points out, Powers et al. teach that the elected peptide are used as “anti-coagulants, anti-inflammatory agents”; the latter being directed to the underlying physiological basis of tissue adhesion and

Art Unit: 1654

reducing thereof, well known in the art to effectively carry out reducing adhesion formation (e.g. use of protease inhibitors in e.g. stents, see below "Prior Art Made of Record (on this point) and Not Relied On", citing by example Porter et al. (US 5,591,199)). The rejection as to the method, products, and forms of administration thereto is maintained.

The remainder of the rejection is repeated below for continuity of record:

Powers et al. is discussed above. Powers et al. teach a pharmaceutical composition in any form (inherently containing a diluent or excipient since can be in the form of e.g. tablet, aqueous or oily suspension, etc.) (col. 16, lines 23-40), comprising the elected compound of the invention Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub> (e.g. Example 17), describes at the "best inhibitor for [serine proteases] chymotrypsin and chymotrysin-like enzymes" (col. 5, lines 40-44; col. 3, lines 50-53), which are involved in "tissue remodeling" [e.g. tissue adhesion formation] (col. 1, lines 41-43). However, Powers et al. does not expressly teach the use of Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub> to reduce [tissue] adhesion formation (e.g. claim 1) or all the various forms of administration (e.g. claim 25-30, such as liposomes).

Scharpe et al. teach the use of serine protease inhibitors such as Suc-Val-Pro-Phe (para 69) in virtually any pharmaceutical admixture/formulation, such as liposomes (para 125).

It would have been obvious to one of ordinary skill in the art at the time of the invention to use the elected compound Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub> to reduce [tissue] adhesion formation as one of the methods relevant to inhibiting the actions of the serine protease chymotrypsin methods in Powers et al., because Powers et al. advantageously teaches the use of Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub> to inhibit chymotrysin, which is a serine protease known to be used in the pathway of

Art Unit: 1654

tissue remodeling (e.g. adhesion/aggregation/binding), and one of skill in the art would recognize that administering Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub>, even if not expressly stated, is administered in part or total to combat such tissue adhesion caused by chymotrypsin.

It would have been obvious to one of ordinary skill in the art at the time of the invention to put the elected compound Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub> in any formulation/admixtures (e.g. liposomes) in the composition of Powers et al, because Scharpe et al. teach that like exact or like serine protease inhibitors may be put in composition with e.g. liposomes, etc. depending on the desired result/administration route; just as Powers et al. likewise discussed in terms of motivation for route/type of administration being left open to the skilled artisan and the desired effect.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention.

Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re*

Art Unit: 1654

*Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

The provisional rejection of claims 1-34 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of copending Application No.

10/544,254 (Miyazaki et al., Publication US 2006/0122101 A1), is maintained for the reasons of record. Applicant argues '254 claims modes of administration via IV, oral, percutaneous that the present application does not claim. This is not found persuasive, as the present rejection is made under obviousness, as such modes of administration are well known the ordinary skilled artisan and merely a matter of routine optimization, including guidance by the present specification, to which these claims are read in light thereof.

The remainder of the rejection is repeated below for continuity of record:

Although the conflicting claims are not identical, they are not patentably distinct from each other because even though the '254 expressly claims its subject matter in the form of a "medicament" only, therein, the limitations are directed to the presently elected compound Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub> in any formulation/admixtures, for the purpose of inhibiting tissue adhesion.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

***Claim Rejections - 35 U.S.C. § 112 1<sup>st</sup> Scope of Enablement***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The rejection of claims 33-34 and new claims 35-36 under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for reducing adhesion formation (as well as postoperatively) between tissue surfaces (see e.g. Fig.'s 4-6, specification) using the protease inhibitor Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub>, for a period of time sufficient to reduce adhesion formation; does not reasonably provide enablement for *preventing* adhesion formation between tissue surfaces using the protease inhibitor Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub>, is maintained for the reasons of record. Applicant has amended the method claims, but not the product claims.

The remainder of the rejection is repeated below for continuity of record:

The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

Applicants have reasonably demonstrated/disclosed that the claimed sequences may be used for reducing adhesion formation between tissue surfaces (see e.g. Fig.'s 4-6, specification) using the protease inhibitor Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub>, for a period of time sufficient to reduce adhesion formation; and/or reducing the risk thereof. However, the claims also encompass using the claimed composition to prevent adhesion formation between tissue surfaces using the



Art Unit: 1654

protease inhibitor Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub>, which is clearly beyond the scope of the instantly disclosed/claimed invention. Please note that the term "prevent" is an absolute definition which means to stop from occurring and, thus, requires a higher standard for enablement than does the term "treat", especially since it is notoriously well accepted in the medical art that the vast majority of afflictions/disorders suffered by mankind cannot be totally prevented with current therapies (other than certain vaccination regimes) - including preventing such disorders as ordinary tissue adhesion (which clearly is not recognized in the medical art as being a totally preventable phenomenon/condition).

Accordingly, it would take undue experimentation without a reasonable expectation of success for one of skill in the art to make and/or use the claimed composition which would function to prevent prevent adhesion formation between tissue surfaces using the protease inhibitor Suc-Val-Pro-Phe<sup>P</sup>(Oph)<sub>2</sub>.

### ***Claim Observations***

As previously noted (Applicant's acknowledgement as well), claims 25-30 depend from claim 1 directly or indirectly, the first independent claim grouping, but are sandwiched in the middle of the second independent claim grouping (claim 16). It is suggested, for clarity (and along with any other amendments) that Applicant consider amending the claims to delete claims 1-34 and start with new claims beginning at claim 25, wherein the claims are properly grouped.

***Prior Art Made of Record and Not Relied Upon***

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Porter et al. (US 5,591,199) teach at col. 5-6 that protease inhibitors are known to be used for reducing aggregation/tissue adhesion, and applied via stents at the site of tissue for such purposes:

*For restenosis inhibition, it is typically desirable to arrest the proliferation of smooth muscle cells. Accordingly, drugs which prevent platelet aggregation and adhesion can be used, such as antiplatelets, antithrombogenics, and anticoagulants. In addition, receptor blockers, growth factors and other hormones may be used to limit the normal repair response. The following are groups of particular drugs which can be used to treat vascular disease, such as atherosclerosis and restenosis: anticoagulants, including heparin, hirudin, hirulog, tissue plasminogen activator, and fibrinogen; anti-inflammatory agents, such as steroids, ibuprofen, aspirin, somatostatin, angiopeptin, and anti-inflammatory peptide 2; cytotoxins, including colchicine, dexamethasone, doxorubicin, methotrexate, and psoralen; antibiotics; and enzymes and enzyme inhibitors, including urokinase, 2,4-dinitrophenol, and thiol protease inhibitor.*

***Conclusion***

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maury Audet whose telephone number is 571-272-0960. The examiner can normally be reached on M-Th. 7AM-5:30PM (10 Hrs.).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1654

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MA, 4/14/2007



CHRISTOPHER R. TATE  
PRIMARY EXAMINER